Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Stopped early · Not applicable
Conditions studied: Chronic Myeloproliferative Disorders, Diamond-blackfan Anemia, Fanconi Anemia, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
In brief
RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a related or unrelated donor, that do not exactly match the patient's blood, are infused into the patient they may help the patient's bone marrow to make stem cells, red blood cells, white blood cells, and platelets. PURPOSE: This clinical trial is studying how well donor umbilical cord blood transplant works in treating patients with hematologic cancer.
Key facts
- Study ID
- NCT00290628
- Run by
- Masonic Cancer Center, University of Minnesota
- People needed
- 43
- Starts
- 1999-10-01
- Expected to finish
- 2007-04-01
- Last updated by the study team
- 2017-11-29
Who can join
Age: any, up to 45. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Minnesota Cancer Center — Minneapolis, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.